Here are the latest quarterly results of WOCKHARDT. For more details, see the WOCKHARDT financial fact sheet and WOCKHARDT share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
3
Mar-22* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 5,983 | 7,141 | 7,640 | 6,320 | 8,596 | 8,620 | 8,539 | 6,550 | |
Other income | Rs m | 80 | 162 | 1,031 | 220 | 149 | 52 | 21 | 140 | |
Turnover | Rs m | 6,062 | 7,303 | 8,672 | 6,540 | 8,745 | 8,672 | 8,559 | 6,690 | |
Expenses | Rs m | 6,703 | 6,974 | 7,082 | 7,120 | 7,520 | 7,662 | 7,424 | 6,880 | |
Gross profit | Rs m | -2,145 | 167 | 558 | -800 | 1,075 | 958 | 1,115 | -2,160 | |
Depreciation | Rs m | 560 | 572 | 679 | 650 | 643 | 612 | 620 | 590 | |
Interest | Rs m | 737 | 609 | 599 | 550 | 641 | 691 | 801 | 860 | |
Profit before tax | Rs m | -3,362 | -851 | 312 | -1,780 | -60 | -292 | -286 | -3,470 | |
Tax | Rs m | -1,107 | -884 | -12 | -710 | 6 | -664 | -303 | -360 | |
Profit after tax | Rs m | -2,256 | 33 | 324 | -1,070 | -66 | 372 | 18 | -3,110 | |
Gross profit margin | % | -35.9 | 2.3 | 7.3 | -12.7 | 12.5 | 11.1 | 13.1 | -33.0 | |
Effective tax rate | % | 32.9 | 103.9 | -3.9 | 39.9 | -9.7 | 227.1 | 106.2 | 10.4 | |
Net profit margin | % | -37.7 | 0.5 | 4.2 | -16.9 | -0.8 | 4.3 | 0.2 | -47.5 | |
Diluted EPS | Rs | -15.7 | 0.2 | 2.2 | -7.4 | -0.5 | 2.6 | 0.1 | -21.6 | |
Diluted EPS (TTM) | Rs | -17.5 | -10.7 | -9.8 | -20.6 | -5.4 | -3.1 | -5.2 | -19.3 | |
![]() |
Asian share markets opened mostly on the back foot today following another tepid lead from Wall Street as traders grew increasingly worried about the impact of surging inflation.
In 2021, R&D of pharma companies roared to life in a never-before-seen way.
These companies are likely to benefit the most from Covid-19 vaccines.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
More Views on NewsWith India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
Some sectors have corrected by 50%. Do they merit a look?
This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.
More